Intercept Pharmaceuticals Performance
| ICPTDelisted Stock | USD 10.31 0.16 1.53% |
The company retains a Market Volatility (i.e., Beta) of 0.8, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, Intercept Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Intercept Pharmaceuticals is expected to be smaller as well. Intercept Pharmaceuticals right now retains a risk of 0.0%. Please check out Intercept Pharmaceuticals maximum drawdown, accumulation distribution, as well as the relationship between the Accumulation Distribution and market facilitation index , to decide if Intercept Pharmaceuticals will be following its current trending patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Intercept Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable basic indicators, Intercept Pharmaceuticals is not utilizing all of its potentials. The current stock price uproar, may contribute to short-horizon losses for the private investors. ...more
| Begin Period Cash Flow | 94.4 M | |
| Total Cashflows From Investing Activities | 261.8 M |
Intercept |
Intercept Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 1,031 in Intercept Pharmaceuticals on October 20, 2024 and sell it today you would earn a total of 0.00 from holding Intercept Pharmaceuticals or generate 0.0% return on investment over 90 days. Intercept Pharmaceuticals is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Intercept, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Intercept Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Intercept Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Intercept Pharmaceuticals, and traders can use it to determine the average amount a Intercept Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| ICPT |
Based on monthly moving average Intercept Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Intercept Pharmaceuticals by adding Intercept Pharmaceuticals to a well-diversified portfolio.
Intercept Pharmaceuticals Fundamentals Growth
Intercept Stock prices reflect investors' perceptions of the future prospects and financial health of Intercept Pharmaceuticals, and Intercept Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Intercept Stock performance.
| Return On Equity | -0.64 | |||
| Return On Asset | -0.0723 | |||
| Profit Margin | (0.19) % | |||
| Operating Margin | 0.02 % | |||
| Current Valuation | 695.84 M | |||
| Shares Outstanding | 41.81 M | |||
| Price To Earning | (3.88) X | |||
| Price To Book | 44.19 X | |||
| Price To Sales | 1.60 X | |||
| Revenue | 285.71 M | |||
| EBITDA | (61.7 M) | |||
| Cash And Equivalents | 404.78 M | |||
| Cash Per Share | 13.58 X | |||
| Total Debt | 332.67 M | |||
| Debt To Equity | 411.20 % | |||
| Book Value Per Share | 1.72 X | |||
| Cash Flow From Operations | (26.78 M) | |||
| Earnings Per Share | (4.26) X | |||
| Total Asset | 553.71 M | |||
| Retained Earnings | (2.14 B) | |||
| Current Asset | 641.69 M | |||
| Current Liabilities | 47.37 M | |||
About Intercept Pharmaceuticals Performance
Assessing Intercept Pharmaceuticals' fundamental ratios provides investors with valuable insights into Intercept Pharmaceuticals' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Intercept Pharmaceuticals is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company was incorporated in 2002 and is headquartered in New York, New York. Intercept Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 437 people.Things to note about Intercept Pharmaceuticals performance evaluation
Checking the ongoing alerts about Intercept Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Intercept Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Intercept Pharmaceuticals is not yet fully synchronised with the market data | |
| Intercept Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| Intercept Pharmaceuticals has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its financial obligations | |
| The company reported the previous year's revenue of 285.71 M. Net Loss for the year was (174.86 M) with profit before overhead, payroll, taxes, and interest of 284.73 M. | |
| Intercept Pharmaceuticals currently holds about 404.78 M in cash with (26.78 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 13.58, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Over 81.0% of the company shares are owned by institutional investors |
- Analyzing Intercept Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Intercept Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Intercept Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Intercept Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Intercept Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Intercept Pharmaceuticals' stock. These opinions can provide insight into Intercept Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Other Consideration for investing in Intercept Stock
If you are still planning to invest in Intercept Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Intercept Pharmaceuticals' history and understand the potential risks before investing.
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation |